Vetoquinol SA
PAR:VETO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Vetoquinol SA
Other Current Liabilities
Vetoquinol SA
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vetoquinol SA
PAR:VETO
|
Other Current Liabilities
€4.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
0%
|
|
|
Sanofi SA
PAR:SAN
|
Other Current Liabilities
€805m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-22%
|
|
|
Ipsen SA
PAR:IPN
|
Other Current Liabilities
€449.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
6%
|
|
|
Virbac SA
PAR:VIRP
|
Other Current Liabilities
€229.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
Boiron SA
PAR:BOI
|
Other Current Liabilities
€24.1m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
2%
|
|
|
Medincell SA
PAR:MEDCL
|
Other Current Liabilities
€7.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Vetoquinol SA
Glance View
Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.
See Also
What is Vetoquinol SA's Other Current Liabilities?
Other Current Liabilities
4.1m
EUR
Based on the financial report for Jun 30, 2025, Vetoquinol SA's Other Current Liabilities amounts to 4.1m EUR.
What is Vetoquinol SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
0%
Over the last year, the Other Current Liabilities growth was -55%. The average annual Other Current Liabilities growth rates for Vetoquinol SA have been -2% over the past three years , -10% over the past five years .
